Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
CG

NASDAQ · CGEN

Compugen Ltd.

Healthcare · Biotechnology

$1.98

Down-$0.06 (-2.94%)

Updated Nov 1, 2026, 8:39 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
150.12M
P/E ratio
-7.75
Dividend yield
0.00%
52-week range
$1.87 – $3.24
Volume
255.46K
Avg. volume
403.79K

Price performance · CGEN

CGEN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

CGEN closed at $1.98 after 20 trading sessions, down 14.29% for the selected period.

Last close
$1.98
Period change
-14.29%
Period low
$1.88
Period high
$2.31
Daily close
View OHLC price history
CGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$2.02$2.0202$1.92$1.98255.46K
Oct 29, 2026$2.02$2.07$2.00$2.04142.9K
Oct 28, 2026$1.96$2.01$1.96$2.01149.27K
Oct 27, 2026$1.92$1.97$1.88$1.97131.41K
Oct 26, 2026$1.95$1.975$1.87$1.875334.47K
Oct 23, 2026$1.97$1.97$1.89$1.94148.02K
Oct 22, 2026$2.11$2.14$1.92$1.96285.55K
Oct 21, 2026$2.15$2.20$2.105$2.12186.97K
Oct 20, 2026$1.96$2.18$1.96$2.14923.3K
Oct 19, 2026$1.97$1.995$1.95$1.97159.25K
Oct 16, 2026$2.08$2.09$1.93$1.96173.44K
Oct 15, 2026$2.02$2.13$2.02$2.08200.14K
Oct 14, 2026$2.01$2.02$1.95$2.00378.14K
Oct 13, 2026$2.09$2.09$1.96$1.98223.64K
Oct 12, 2026$2.13$2.13$2.07$2.0786.47K
Oct 9, 2026$2.13$2.13$2.08$2.13123.36K
Oct 8, 2026$2.14$2.16$2.04$2.12243.15K
Oct 7, 2026$2.22$2.225$2.13$2.15201.81K
Oct 6, 2026$2.32$2.331$2.205$2.22265.38K
Oct 5, 2026$2.30$2.32$2.25$2.31198.87K

Latest CGEN news

The latest Smart Investors Daily articles mentioning CGEN.

Stock researchCompany · Overview

CGEN research

Overview

Company profile and research snapshot.

Company profile

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
CGEN recent ratings
DateFirmRatingTarget
Oct 12, 2026HC Wainwright & Co.Buy—
May 21, 2026Leerink PartnersOutperform—
Apr 7, 2026Lake StreetBuy—
Jan 7, 2026HC Wainwright & Co.Buy—
May 21, 2024Truist SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, today announced that the Company will release its third quarter 2026 financial results on Monday, November 9, 2026, before the U.S. financial markets open. That same day, management will host a conference call to review the results and provide a corporate update at 8:30 AM ET.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By